explore -WSS

explore

author：leisure time 2025-09-06 03:55:01 - browse：911

Traffic on the Longfellow Bridge and the Kendall Square skyline are seen. -- health coverage from STAT — Michael Dwyer/AP

Around this time three years ago, while most of us navigated pandemic life, real estate developers across Greater Boston looked to life-science laboratories, and saw dollar signs.

The white-collar office workers who’d long filled downtown towers were largely staying home (unless they worked in commercial real estate). The future of cities had rarely been murkier.

But many biotech companies, like Cambridge’s Moderna, were busier than ever, and growing fast. Life-science companies, and the lab buildings that house them, looked like a sure bet for investors. Money poured in to drug companies by the billions — from venture capitalists, the stock market, the National Institutes of Health. And big real estate investors followed, launching a wave of speculative lab development all over Greater Boston.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Physicians and social media: If you see something, say something?

knowledge

WSS

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Zyn nicotine pouches become unlikely player in latest culture war

White House pharmacy plagued with problems, investigation finds

Creating egg and sperm cells from stem cells raises ethical issues

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Gene editing the human germline: What are the risks?

explore

explore

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Pancreatic cancer early detection could be helped by AI

23andMe had bad news about my health. I wish a person had delivered it

Creating egg and sperm cells from stem cells raises ethical issues

Peter Hotez and the public health issue of online harassment

Stop the failed accountable care organization experiment

Affirmative action in medical school literally saved lives

Virtual Event: March of the Biosimilars

Wikipedia

Baby aspirin cuts fat buildup in liver disease patients, in small study

How generative AI ratchets up security threats for health systems

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Biogen walks away from Aduhelm, years after polarizing approval

White House pharmacy plagued with problems, investigation finds

AstraZeneca to buy developer of next

focus

knowledge

explore

leisure time